The two-year postoperative clinical data showed OsteoSponge equivalent to recombinant bone morphogenic protein in achieving interbody fusion. Patients who received OsteoSponge also reported significantly less leg pain than patients who received rhBMP-2.
The product is used in conjunction with patients’ own bone marrow aspirate. Since its release, OsteoSponge has been implanted more than 100,000 times.
Related Articles on Spine Surgery:
Surgery for Herniated Disc Within 6 Months of Symptom Appearance Shows Best Outcomes
Where Infuse Stands: 6 Points on the Controversial Spinal Fusion Product
Minimally Invasive Spine Surgery Registries Gather Support From Device Companies
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
